HOLX - Hologic, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
37.01
-0.07 (-0.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close37.08
Open37.23
Bid30.00 x 100
Ask46.65 x 100
Day's Range36.94 - 37.37
52 Week Range35.15 - 46.80
Volume2,340,233
Avg. Volume3,329,841
Market Cap10.38B
Beta0.59
PE Ratio (TTM)13.78
EPS (TTM)2.68
Earnings DateNov 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.43
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Hologic Inc.
    Markityesterday

    See what the IHS Markit Score report has to say about Hologic Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Morningstar3 days ago

    15 Cheap Stocks That Could Launch the 'Next Big Thing'

    Take a look at Morningstar analysts' nine 'exponential technology' themes and some undervalued stocks poised to benefit from them.

  • 3 Plastic & Reconstructive Surgery Stocks Looking Good
    Zacks10 days ago

    3 Plastic & Reconstructive Surgery Stocks Looking Good

    Consider these three stocks for raking in grand returns from the fast-growing plastic and reconstructive surgery market.

  • Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
    Zacks15 days ago

    Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval

    Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.

  • PR Newswire16 days ago

    Panther Fusion® Flu A/B/RSV Assay Now FDA Cleared on Hologic's New Panther Fusion® System

    The Panther Fusion is available as a full system or the Panther Fusion module can be attached to existing Panther systems in the field to extend testing capabilities.  Specifically, the Panther Fusion adds the capacity to run PCR (polymerase chain reaction) assays in addition to tests based on TMA (transcription-mediated amplification), the proprietary Hologic chemistry that powers the Company's Aptima® brand. "Consolidating testing remains a key focus of our clinical laboratory customers," said Tom West, president of the Diagnostic Solutions Division at Hologic.

  • PR Newswire17 days ago

    Hologic Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 4.375% Senior Notes Due 2025

    MARLBOROUGH, Mass., Oct. 4, 2017 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that it has priced its previously announced private offering of $350 million aggregate principal amount of 4.375% senior notes due 2025 at an issue price of $1,000 per $1,000.  The 2025 notes will be unsecured obligations of the Company and will be guaranteed by certain subsidiaries.  The offering is expected to close on October 10, 2017, subject to customary closing conditions. Hologic intends to use the net proceeds of the offering and available cash, including funds from its new five-year secured credit agreement, to retire the Company's remaining convertible notes, including through repurchases or redemptions, when they become callable in December of 2017 and March of 2018. The 2025 notes will not be registered under the Securities Act of 1933, as amended, or any state securities laws.  Unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.  The 2025 notes are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act, and outside the United States in accordance with Regulation S under the Securities Act.

  • Moody's17 days ago

    Hologic, Inc. -- Moody's assigns Ba3 to Hologic's senior unsecured bonds

    Rating Action: Moody's assigns Ba3 to Hologic's senior unsecured bonds. Global Credit Research- 04 Oct 2017. New York, October 04, 2017-- Moody's Investors Service assigned a Ba3 rating to Hologic, Inc.' ...

  • Is Hologic Inc’s (HOLX) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.17 days ago

    Is Hologic Inc’s (HOLX) PE Ratio A Signal To Buy For Investors?

    Hologic Inc (NASDAQ:HOLX) trades with a trailing P/E of 13.8x, which is lower than the industry average of 43.5x. While HOLX might seem like an attractive stock to buy, itRead More...

  • PR Newswire17 days ago

    Hologic Enters into Amended and Restated Five-Year Secured Credit Agreement

    MARLBOROUGH, Mass., Oct. 4, 2017 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that the Company has entered into an amended and restated credit agreement consisting of a new, five-year $1.5 billion senior term loan and $1.5 billion revolving credit facility. The new loan facilities mature on October 3, 2022, subject to adjustment in certain circumstances.  Borrowings initially bear interest at an annual rate of LIBOR + 1.50%, and may change based on Hologic's leverage ratio.  Prior to maturity, the Company will be required to make minimum principal payments on the new term loan in annualized amounts of $37.5 million in fiscal 2018, $75 million in fiscal 2019, $75 million in fiscal 2020, $112.5 million in fiscal 2021, and $150 million in fiscal 2022, with the balance due at maturity.

  • PR Newswire17 days ago

    Hologic Announces Offering of $350 Million of Senior Notes Due 2025

    MARLBOROUGH, Mass., Oct. 4, 2017 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $350 million aggregate principal amount of senior notes due 2025.  Hologic intends to use the proceeds of the offering and available cash, including funds from its new five-year secured credit agreement, to retire the Company's remaining convertible notes, including through repurchases or redemptions, when they become callable in December of 2017 and March of 2018. The 2025 notes will not be registered under the Securities Act of 1933, as amended, or any state securities laws.  Unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities law.  The 2025 notes are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act, and outside the United States in accordance with Regulation S under the Securities Act.

  • PR Newswire18 days ago

    Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2017 on Wednesday, November 8, 2017

    MARLBOROUGH, Mass. , Oct. 3, 2017 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2017 on Wednesday, ...

  • GlobeNewswire22 days ago

    Hologic, Inc. (Nasdaq: HOLX) to Ring The Nasdaq Stock Market Opening Bell

    What: Hologic, Inc., an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment, will visit the Nasdaq MarketSite in Times ...

  • PR Newswire22 days ago

    Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2 to Kick Off Breast Cancer Awareness Month

    Trailblazing Company Behind the Genius™ 3D Mammography™ Exam Celebrates Year of Innovations in Breast Health MARLBOROUGH, Mass. , Sept. 29, 2017 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today ...

  • Capital Cube23 days ago

    ETFs with exposure to Hologic, Inc. : September 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hologic, Inc. Here are 5 ETFs with the largest exposure to HOLX-US. Comparing the performance and risk of Hologic, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Hologic, Inc. :HOLX-US: Earnings Analysis: Q3, 2017 By the Numbers : September 27, 2017
    Capital Cube24 days ago

    Hologic, Inc. :HOLX-US: Earnings Analysis: Q3, 2017 By the Numbers : September 27, 2017

    Categories: Yahoo FinanceGet free summary analysis Hologic, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Hologic, Inc. – Becton, Dickinson and Company (BDX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 806.10 million, Net Earnings of USD 59.50 million. ... Read more (Read more...)

  • PR Newswire24 days ago

    Hologic Receives FDA 510(k) Clearance to Market SculpSure® for Non-Invasive Body Contouring (Lipolysis) of the Submental Area (Under the Chin)

    MARLBOROUGH, Mass., Sept. 27, 2017 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted an expanded FDA 510(k) clearance for Cynosure's non-invasive body contouring product, SculpSure®. The state-of-the-art body contouring laser treatment is now cleared to treat a double chin (also known as the submental area), marking the product's sixth cleared body treatment area.

  • Hologic Introduces a More Comfortable Mammogram with the Launch of the SmartCurve™ Breast Stabilization System
    PR Newswire25 days ago

    Hologic Introduces a More Comfortable Mammogram with the Launch of the SmartCurve™ Breast Stabilization System

    For years, women have reported avoiding regular mammograms due in large part to the fear of discomfort associated with breast compression. In fact, a recent survey of 10,000 women found that fear of physical discomfort was the top reason cited for avoiding a mammogram by women who never had one.5 With this in mind, Hologic's research and development team, led by Tracy Accardi, Global Vice President of Research and Development, set out to reduce breast pain without compromising image quality or exam accuracy.

  • PR Newswirelast month

    New USPSTF Draft Cervical Cancer Screening Recommendations Are a Step Back for Women's Health, Would Put Lives at Risk

    MARLBOROUGH, Mass. , Sept. 14, 2017 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) is deeply concerned that the United States Preventive Services Task Force (USPSTF) did not include a grade for co-testing ...

  • Associated Presslast month

    Western Digital and Hologic skid; Centene, Nordstrom climb

    Stocks that moved substantially or traded heavily on Wednesday: Centene Corp., up $7.28 to $98.16 The health insurer and Medicaid coverage provider will expand into New York by buying Fidelis Care for ...

  • Hologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound?
    Zackslast month

    Hologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound?

    Hologic (HOLX) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Moody'slast month

    GMAC Commercial Mortgage Securities, Inc. Series 2003-C1 -- Moody's Affirms Five Classes of GMACC 2003-C1

    Rating Action: Moody's Affirms Five Classes of GMACC 2003- C1. Global Credit Research- 08 Sep 2017. Approximately $10.4 Million of Structured Securities Affected.

  • Hologic (HOLX) Launches Brevera, Progresses in Breast Health
    Zacks2 months ago

    Hologic (HOLX) Launches Brevera, Progresses in Breast Health

    Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.

  • Hologic Announces Availability of New Brevera® Breast Biopsy System with CorLumina® Imaging Technology
    PR Newswire2 months ago

    Hologic Announces Availability of New Brevera® Breast Biopsy System with CorLumina® Imaging Technology

    MARLBOROUGH, Mass., Aug. 31, 2017 /PRNewswire/ -- Hologic, Inc. (HOLX) today announced U.S. commercial availability of the Brevera® breast biopsy system with CorLumina® imaging technology, a groundbreaking real-time breast biopsy and verification system that enhances workflow, improves the patient experience and streamlines the entire biopsy process from start to finish. The first-of-its-kind Brevera system is designed to increase biopsy accuracy with real-time imaging that delivers valuable information at the point of care, enabling clinicians to make informed decisions with confidence. The Brevera system is the world's first and only breast biopsy solution to combine tissue acquisition, real-time imaging, sample verification and advanced post-biopsy handling in one, integrated system.

  • Kahn Brothers Curbs Hologic, Citigroup, Pfizer Postitions, Exits GE
    GuruFocus.com2 months ago

    Kahn Brothers Curbs Hologic, Citigroup, Pfizer Postitions, Exits GE

    The firm's 9 largest sales for the 2nd quarter

  • Hologic CEO: Next-gen mammograms improve patient experien...
    CNBC Videos19 days ago

    Hologic CEO: Next-gen mammograms improve patient experien...

    Steve MacMillan, Hologic CEO talks about the quest to find improved detection and treatment for breast cancer.